Healthcare
LB Pharmaceuticals Inc Common Stock(LBRX)
Live Price
Offline$30.00
-0.17% today
Window Change
+64.74%
Window
Sep 11, 2025 β Jun 15, 2026
- Market Cap
- $900.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +94.4%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 190 bars Β· Sep 11, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
LB Pharmaceuticals Inc Common Stock (LBRX) is a Healthcare stock with a market cap of $900.00M and listed on NASDAQ. The stock last traded around $30.00 and up 64.7% across the available one-year price window (Sep 11, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +94.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +94.4%, free cash flow +34.5% with operating margin 0.0% and ROIC -9.9%. Stock Foundry combines LBRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 25, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +94.4%, while operating margin sits near 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Jun 25, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 15, 2026 | β | -6.5% | -5.2% | -3.9% |
2026 Mar 26, 2026 | +0.0% | -2.8% | +4.7% | +25.3% |
2025 Nov 6, 2025 | -7.0% | -1.0% | -3.9% | +25.7% |
Benchmark Edge
LBRX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LBRX
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LBRX Max Drawdown
-17.82%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LBRX and SPY.
Company Overview
LB Pharmaceuticals Inc Common Stock
NASDAQ Global Select
Clinicalβstage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LBβ102, a methylated derivative of amisulpride.
- Leadership
- Heather D. Turner
- IPO Date
- Sep 11, 2025
- Employees
- 16
- Street Address
- One Pennsylvania Plaza
- Mailing
- New York, NY, 10119
- Region
- New York, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 605 0300
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- 2.6
Growth
- Revenue
- 0.0%
- EPS
- +94.4%
- Free Cash Flow
- +34.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -19.5%
- ROIC
- -9.9%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 41.44
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.